IMMX
Immix Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.22
+3.01%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 21.6M | 16.3M | 11.3M | 8.7M | 4.2M |
| SG&A Expense | 20.2M | 13.7M | 11.4M | 7.4M | 4.0M |
| General & Admin Expense | 20.2M | 13.7M | 11.4M | 7.4M | 4.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 41.8M | 30.0M | 22.7M | 16.1M | 8.2M |
| Cost and Expenses | 41.8M | 30.0M | 22.7M | 16.1M | 8.2M |
| Operating Income (EBIT) | (41.8M) | (30.0M) | (22.7M) | (16.1M) | (8.2M) |
| Non-Operating | |||||
| Interest Income | 1.9M | 555.5K | 1.0M | 572.0K | — |
| Interest Expense | — | — | — | — | 497.00 |
| Net Interest Income | 1.9M | 555.5K | 1.0M | 572.0K | (497.00) |
| Other Non-Op Income/Expense | 1.9M | 555.5K | 1.0M | 572.0K | (497.00) |
| Non-Operating Income (excl Interest) | (1.2M) | — | (1.0M) | (572.0K) | — |
| EBT (Pre-Tax Income) | (39.9M) | (29.4M) | (21.7M) | (15.6M) | (8.2M) |
| Income Tax Expense | 33.3K | 37.7K | 41.0K | 26.4K | 10.3K |
| Bottom Line | |||||
| Net Income | (39.9M) | (29.4M) | (21.6M) | (15.4M) | (8.2M) |
| Earnings from Cont. Ops | (39.9M) | (29.4M) | (21.7M) | (15.6M) | (8.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (39.9M) | (29.4M) | (21.6M) | (15.4M) | (8.2M) |
| Per Share | |||||
| Basic EPS | ($0.88) | ($0.89) | ($0.76) | ($0.89) | ($0.59) |
| Diluted EPS | ($0.88) | ($0.89) | ($0.76) | ($0.89) | ($0.59) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 63.8M | 33.0M | 28.3M | 17.3M | 13.9M |
| Diluted Shares Outstanding | 63.8M | 33.0M | 28.3M | 17.3M | 13.9M |
| Profitability Metrics | |||||
| EBITDA | (40.1M) | (29.6M) | (21.5M) | (15.6M) | (8.2M) |
| D&A | 487.1K | 364.5K | 115.4K | 5.5K | 2.1K |
| EBIT | (40.6M) | (30.0M) | (21.7M) | (15.6M) | (8.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026